Erik Schropp
Director/Board Member chez POLYPEPTIDE GROUP AG
Fortune : 107 414 $ au 31/03/2024
Profil
Erik Schropp is currently the Chief Executive Officer at C&P Investors Ltd., Director at Haydn Holding AB, Non-Executive Director at PolyPeptide Group AG, Director at SEVER Life Sciences BV, Director at Draupnir Holding BV, Director at Svar Life Science AB, and Director at Ferring Foundation BV.
Previously, he worked as the Director-International Tax & Finance at Ferring Pharmaceuticals A, Director at Altacor Ltd., Director at PolyPeptide Laboratories Holding BV, Director at PolyPeptide Laboratories Holding (PPL) AB, and Director at FinVector Oy.
He also worked as the Manager-International Tax at Unisource NV and Tax Manager at Arthur Andersen Accountants.
Mr. Schropp graduated from Erasmus University Rotterdam in 1988.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG
0,01% | 31/12/2022 | 3 193 ( 0,01% ) | 107 414 $ | 31/03/2024 |
Postes actifs de Erik Schropp
| Sociétés | Poste | Début |
|---|---|---|
| POLYPEPTIDE GROUP AG | Director/Board Member | 01/01/2021 |
| C&P Investors Ltd. | Chief Executive Officer | 01/01/2020 |
Draupnir Holding BV
 Draupnir Holding BV Miscellaneous Commercial ServicesCommercial Services Draupnir Holding BV provides organizational, business, and management consulting services. The private company is based in Hoofddorp, Netherlands. | Director/Board Member | 01/01/2008 |
| SEVER Life Sciences BV | Director/Board Member | 01/01/2019 |
Svar Life Science AB
 Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Director/Board Member | 01/01/2008 |
| Haydn Holding AB | Director/Board Member | 01/01/2012 |
Ferring Foundation BV
 Ferring Foundation BV Financial ConglomeratesFinance Part of Ferring Pharmaceuticals BV/NL/, Ferring Foundation BV functions as an investment holding and Dutch management company. The private company is based in Hoofddorp, Netherlands. | Director/Board Member | 01/01/2008 |
Anciens postes connus de Erik Schropp
| Sociétés | Poste | Fin |
|---|---|---|
PolyPeptide Laboratories Holding BV
 PolyPeptide Laboratories Holding BV Financial ConglomeratesFinance Part of Draupnir Corp. NV, PolyPeptide Laboratories Holding BV is an investment holding Dutch company. The private company is based in Hoofddorp, Netherlands. | Director/Board Member | 01/01/2021 |
PolyPeptide Laboratories Holding (PPL) AB
 PolyPeptide Laboratories Holding (PPL) AB Financial ConglomeratesFinance PolyPeptide Laboratories Holding (PPL) AB manufactures commercial therapeutic peptides. The firm offers polypeptide, custom peptide synthesis, peptide synthesis, and generic peptide. The company was founded in 1996 and is headquartered in Malmo, Sweden. | Director/Board Member | 01/01/2021 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Erik Schropp
| Erasmus University Rotterdam | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POLYPEPTIDE GROUP AG | Health Technology |
| Entreprise privées | 13 |
|---|---|
Unisource NV
 Unisource NV Specialty TelecommunicationsCommunications Unisource NV provides telecommunications services. The company is a holding company that owns and operates subsidiaries including Deutsche Telekom, AT&T-Unisource Communications Services, and Unisource Carrier Services. It was founded in 1992 and is headquartered in Hoofddorp, the Netherlands. | Communications |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Health Technology |
PolyPeptide Laboratories Holding BV
PolyPeptide Laboratories Holding BV Financial ConglomeratesFinance Part of Draupnir Corp. NV, PolyPeptide Laboratories Holding BV is an investment holding Dutch company. The private company is based in Hoofddorp, Netherlands. | Finance |
PolyPeptide Laboratories Holding (PPL) AB
PolyPeptide Laboratories Holding (PPL) AB Financial ConglomeratesFinance PolyPeptide Laboratories Holding (PPL) AB manufactures commercial therapeutic peptides. The firm offers polypeptide, custom peptide synthesis, peptide synthesis, and generic peptide. The company was founded in 1996 and is headquartered in Malmo, Sweden. | Finance |
Arthur Andersen Accountants
 Arthur Andersen Accountants Miscellaneous Commercial ServicesCommercial Services Part of Ernst & Young Global Ltd., Arthur Andersen Accountants is a Dutch company that provides accounting services. The private company is based in Rotterdam, Netherlands. | Commercial Services |
| Haydn Holding AB | |
| C&P Investors Ltd. | |
FinVector Oy
 FinVector Oy Pharmaceuticals: MajorHealth Technology Part of Ferring Ventures, FinVector Oy is a Finnish biopharmaceutical company that specializes in manufacturing viral-based gene therapy products. The private company is based in Kuopio, Finland, and has extensive experience in cgmp manufacturing. FinVector employs hundreds of highly qualified professionals from over 40 different countries and works on cutting-edge biopharmaceuticals. It has invested in building state-of-the-art gmp facilities for viral vector platforms. The company was founded in 1993 by Seppo Ylä-Herttuala, and the CEO is Giuseppe Carloni. | Health Technology |
| SEVER Life Sciences BV | |
Draupnir Holding BV
Draupnir Holding BV Miscellaneous Commercial ServicesCommercial Services Draupnir Holding BV provides organizational, business, and management consulting services. The private company is based in Hoofddorp, Netherlands. | Commercial Services |
Svar Life Science AB
Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Commercial Services |
Ferring Foundation BV
Ferring Foundation BV Financial ConglomeratesFinance Part of Ferring Pharmaceuticals BV/NL/, Ferring Foundation BV functions as an investment holding and Dutch management company. The private company is based in Hoofddorp, Netherlands. | Finance |
Altacor Ltd.
 Altacor Ltd. Pharmaceuticals: MajorHealth Technology Altacor Ltd. operates as a specialist ophthalmology company develops and markets a portfolio of products in the fields of dry eye, glaucoma and ocular infection. The company was founded by Francesca Elizabeth Crawford and David Francis Alcraft in 2007 and is headquartered in Theale, the United Kingdom. | Health Technology |
